ethambutol has been researched along with thioridazine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Aínsa, JA; Martín, C; Ramón-García, S; Thompson, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Deshpande, D; Gumbo, T; Musuka, S; Srivastava, S | 1 |
| Deshpande, D; Gumbo, T; Sherman, CM; Srivastava, S | 1 |
| Chiang, TK; Kurup, SK; White, KM; Yu, M | 1 |
2 review(s) available for ethambutol and thioridazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Use of Visual Electrophysiology to Monitor Retinal and Optic Nerve Toxicity.
Topics: Amiodarone; Cefuroxime; Chlorpromazine; Cisplatin; Deferoxamine; Digoxin; Electrophysiology; Ethambutol; Evoked Potentials, Visual; Humans; Hydroxychloroquine; Isotretinoin; Optic Nerve; Phosphodiesterase 5 Inhibitors; Quinine; Retina; Tamoxifen; Thioridazine; Topiramate; Vigabatrin | 2022 |
5 other study(ies) available for ethambutol and thioridazine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
Topics: Antitubercular Agents; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Clofazimine; Dithiothreitol; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Glutathione; Hydrogen Peroxide; Membrane Transport Proteins; Mutation; Mycobacterium tuberculosis; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Rifampin; Valinomycin | 2009 |
Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Drug Resistance; Ethambutol; Half-Life; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Phenothiazines; Thioridazine | 2016 |
A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Azithromycin; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Monocytes; Moxifloxacin; Mycobacterium avium Complex; Thioridazine; THP-1 Cells | 2017 |